Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REDUCE-IT
2011-004726-10Phase 3Completed
- Sponsor
- Amarin Corporation plc
- Start
- Jan 2012
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hypertriglyceridemia and cardiac morbidity comparing Icosapent ethyl with Placebo (2 arms). Primary endpoint: Primary efficacy endpoint. Started Jan 2012; status: completed.
02
Drugs
omega-3-acid triglycerides
03
Conditions
hypertriglyceridemiacardiac morbidity
Beyond the preview
Go deeper on 2011-004726-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004726-10.